Compare AstraZeneca plc (AZN) vs Baidu Inc (BIDU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Baidu Inc — how do they compare? AstraZeneca plc trades at $158.48 (market cap $248.14B), while Baidu Inc trades at $104.38 (market cap $36.18B). The key difference: AstraZeneca plc is far larger — about 6.9× Baidu Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Baidu Inc pays none. Which is the better fit depends on your goals.
| AZN | BIDU | |
|---|---|---|
Market Cap | $248.14B | $36.18B |
Sector | Health | Media |
52-Week High | $209.48 | $162.52 |
52-Week Low | $147.06 | $86.76 |
Enterprise Value | $275.41B | $32.81B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Baidu (BIDU) trades at $104.41, down 4.65% today amid broader pressure on Chinese stocks. The stock shows a bearish technical signal, with recent earnings missing expectations in Q1 2026. Revenue declined to $129.08B in 2025, and net income margin compressed to 1.02%. However, analyst consensus remains strongly bullish with a $169.80 price target, and the company is advancing AI initiatives, including autonomous vehicle testing in London.
The outlook is mixed: strong analyst support and AI growth potential offer upside, but weak profitability, declining revenue, and macroeconomic risks in China pose significant challenges. Investors should weigh the high P/E of 78.19 against future AI-driven earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →
